Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab
The immune checkpoint inhibitors opened a new era for the treatment of melanoma. Nowadays, combined immune checkpoint inhibitors are administered to provide additive or synergistic effects on anti-melanoma immunity. The use of these drugs comes with serious adverse events related to excessive immune...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.573527/full |
| _version_ | 1831648048503062528 |
|---|---|
| author | S. Morteza Seyed Jafari Laurence Feldmeyer Robert E. Hunger |
| author_facet | S. Morteza Seyed Jafari Laurence Feldmeyer Robert E. Hunger |
| author_sort | S. Morteza Seyed Jafari |
| collection | DOAJ |
| description | The immune checkpoint inhibitors opened a new era for the treatment of melanoma. Nowadays, combined immune checkpoint inhibitors are administered to provide additive or synergistic effects on anti-melanoma immunity. The use of these drugs comes with serious adverse events related to excessive immune activation. Here, we present development of extragenital lichen sclerosus in a patient with metastatic malignant melanoma, during the combined therapy with checkpoint inhibitors. |
| first_indexed | 2024-12-19T14:24:20Z |
| format | Article |
| id | doaj.art-f783753c0d4b4756b192436e447d4983 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-19T14:24:20Z |
| publishDate | 2020-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-f783753c0d4b4756b192436e447d49832022-12-21T20:17:40ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-10-011010.3389/fonc.2020.573527573527Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With NivolumabS. Morteza Seyed JafariLaurence FeldmeyerRobert E. HungerThe immune checkpoint inhibitors opened a new era for the treatment of melanoma. Nowadays, combined immune checkpoint inhibitors are administered to provide additive or synergistic effects on anti-melanoma immunity. The use of these drugs comes with serious adverse events related to excessive immune activation. Here, we present development of extragenital lichen sclerosus in a patient with metastatic malignant melanoma, during the combined therapy with checkpoint inhibitors.https://www.frontiersin.org/article/10.3389/fonc.2020.573527/fullcheckpoint inhibitorsextragenital lichen sclerosus et atrophicusipilimumabmalignant melanomametastaticnivolumab |
| spellingShingle | S. Morteza Seyed Jafari Laurence Feldmeyer Robert E. Hunger Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab Frontiers in Oncology checkpoint inhibitors extragenital lichen sclerosus et atrophicus ipilimumab malignant melanoma metastatic nivolumab |
| title | Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab |
| title_full | Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab |
| title_fullStr | Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab |
| title_full_unstemmed | Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab |
| title_short | Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab |
| title_sort | development of extragenital lichen sclerosus in malignant melanoma patients treated with ipilimumab in combination with nivolumab |
| topic | checkpoint inhibitors extragenital lichen sclerosus et atrophicus ipilimumab malignant melanoma metastatic nivolumab |
| url | https://www.frontiersin.org/article/10.3389/fonc.2020.573527/full |
| work_keys_str_mv | AT smortezaseyedjafari developmentofextragenitallichensclerosusinmalignantmelanomapatientstreatedwithipilimumabincombinationwithnivolumab AT laurencefeldmeyer developmentofextragenitallichensclerosusinmalignantmelanomapatientstreatedwithipilimumabincombinationwithnivolumab AT robertehunger developmentofextragenitallichensclerosusinmalignantmelanomapatientstreatedwithipilimumabincombinationwithnivolumab |